Nucleus Network conduct Phase 1 study of Strep A vaccine

Nucleus Network recently conducted a Phase 1 clinical trial to evaluate vaccine candidates for Strep A infections.

Strep A is a common and potentially deadly bacteria that causes sore throats, scarlet fever and skin conditions.

A vaccine may help protect those most at risk, such as young children, the elderly, pregnant women, Indigenous Australians as well as other people with chronic health conditions.

There is no vaccine available at the moment, current treatments are limited to antibiotics.

The study involved 25 volunteers, aged 18-40 years who stayed at Nucleus Network, a phase 1 clinical trials unit based in Melbourne for up to six days with blood tests and saliva and throat swabs collected regularly.

The results of the study were published in The Lancet Microbe on April 15th, 2021.